Your session is about to expire
← Back to Search
Vaccine
HPV Vaccine Reminder Intervention for Healthy Young Men
N/A
Waitlist Available
Led By Paul Reiter, PhD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Cisgender male
Ages 18-25
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to 9 months
Awards & highlights
No Placebo-Only Group
Summary
This trial will study how well a population-targeted, individually-tailored mHealth intervention that includes vaccine reminders works in increasing HPV vaccine initiation and completion among unvaccinated young sexual minority individuals.
Who is the study for?
This trial is for young cisgender males aged 18-25 in the US who identify as gay, bisexual, or queer, have not had any HPV vaccine doses, and can give informed consent. Participants must be able to read English and should not have taken part in the pilot study.
What is being tested?
The trial tests the 'Outsmart HPV' intervention designed to increase HPV vaccine uptake among sexual minority males. It includes personalized mobile health components like reminders to initiate and complete the vaccination process.
What are the potential side effects?
Since this trial focuses on an informational intervention rather than a medical treatment, traditional side effects are not applicable. However, participants may experience inconvenience or privacy concerns related to receiving text messages.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am a cisgender male.
Select...
I am between 18 and 25 years old.
Select...
I have never received an HPV vaccine.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline up to 9 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to 9 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Changes in Theoretical Constructs
Counts of Human Papillomavirus (HPV) Vaccine Initiation by Participant Characteristics
Human Papillomavirus (HPV) Vaccine Initiation and Completion
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Group C (Outsmart HPV, interactive vaccine reminders)Experimental Treatment3 Interventions
Participants receive Outsmart HPV with interactive vaccine reminders (i.e. reminders that allow participants to respond).
Group II: Group B (Outsmart HPV, unidirectional vaccine reminders)Experimental Treatment3 Interventions
Participants receive Outsmart HPV with unidirectional vaccine reminders (i.e. reminders that do not give participants the option to respond).
Group III: Group A (standard HPV information)Active Control2 Interventions
Participants receive standard information about HPV and HPV vaccine via a mobile-friendly website.
Find a Location
Who is running the clinical trial?
Ohio State University Comprehensive Cancer CenterLead Sponsor
339 Previous Clinical Trials
290,943 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,887 Previous Clinical Trials
41,019,801 Total Patients Enrolled
Paul Reiter, PhDPrincipal Investigator - Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
2 Previous Clinical Trials
253 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I identify as part of the sexual minority, including gay, bisexual, or queer.I am a cisgender male.I am between 18 and 25 years old.I have never received an HPV vaccine.
Research Study Groups:
This trial has the following groups:- Group 1: Group C (Outsmart HPV, interactive vaccine reminders)
- Group 2: Group A (standard HPV information)
- Group 3: Group B (Outsmart HPV, unidirectional vaccine reminders)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger